Ser328

Site Information
ELAGNTSsPPLsPGR SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 4782422

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 )
Disease tissue studied:	leukemia ( 2 ) , acute myelogenous leukemia ( 2 )
Relevant cell line - cell type - tissue:	Jurkat (T lymphocyte) ( 1 , 3 , 4 ) , KG-1 (myeloid) ( 2 )

Upstream Regulation
Treatments:	anti-CD3 ( 3 )

References
1	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
2	Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56 22115753 Curated Info
3	Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46 19690332 Curated Info
4	Stokes M (2008) CST Curation Set: 3885; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info